Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company
- Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
- Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
- Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
- Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.